Novel index for the prediction of significant liver fibrosis and cirrhosis in chronic hepatitis B patients in China

Table 3 Comparisons of the receiver operating characteristic curve between different non-invasive indices

	Training cohort (n = 296)						Validation cohort (n = 211)
	F0-1 vs F2-4		F0-2 vs F3-4		F0-3 vs F4		F0-1 vs F2-4		F0-2 vs F3-4			F0-3 vs F4
AGPR
AUROC (95%CI)	0.83 (0.78-0.87)		0.84 (0.79-0.88)		0.87 (0.83-0.91)		0.83 (0.77-0.88)		0.83 (0.77-0.89)			0.84 (0.78-0.89)
Cut-off values	0.87		1.20		1.40		0.87		1.20			1.40
Se/Sp (%)	83.1/73.4		72.22/80.3		88.6/75.4		85.5/68.1		78.7/70.2			92.3/67.0
PPV/NPV (%)	83.5/72.8		67.8/83.4		38.6/97.4		76.9/79.0		61.8/84.4			28.2/98.4
Positive/negative LR	3.13/0.23		3.67/0.35		3.60/0.15		2.68/0.21		2.65/0.30			2.80/0.11
HR (95%CI)	8.48 (5.22-14.33)		7.56 (4.76-9.83)		8.10 (5.11-11.63)		8.02 (4.95-15.62)		7.06 (4.51-12.35)			5.06 (3.89-7.72)
GPR
AUROC (95%CI)	0.77 (0.72-0.82)		0.81 (0.76-0.85)		0.80 (0.75-0.84)		0.80 (0.74-0.85)		0.81 (0.74-0.87)			0.78 (0.71-0.83)
Cut-off values	0.32		0.32		0.56		0.32		0.32			0.56
Se/Sp (%)	73.7/70.8		76.8/54.8		79.5/65.9		86.3/67.0		91.2/56.5			75.0/62.3
PPV/NPV (%)	80.4/62.5		49.4/80.5		28.9/94.9		76.5/79.7		56.2/91.4			26.5/86.9
Positive/negative LR	2.53/0.37		1.70/0.42		2.33/0.31		2.62/0.20		2.10/0.15			1.95/0.41
HR (95%CI)	6.53 (4.81-9.62)		6.72 (3.96-9.63)		6.47 (4.08-9.83)		6.45 (3.58-11.61)		7.30 (3.87-14.62)			4.84 (3.28-7.95)
APRI
AUROC (95%CI)	0.72 (0.67-0.77)		0.70 (0.64-0.75)		0.76 (0.70-0.81)		0.76 (0.70-0.82)		0.74 (0.67-0.82)			0.77 (0.70-0.83)
Cut-off values	0.5	1.5	-		1.0	2.0	0.5	1.5	-	1.0		2.0
Se/Sp (%)	80.9/58.4	36.1/79.7	-		77.3/64.7	43.2/83.3	83.8/54.3	34.1/76.6	-	70.1/68.6		50.1/78.3
PPV/NPV (%)	75.9/65.3	74.2/43.5	-		27.6/94.2	31.1/89.4	69.5/72.9	64.5/48.3	-	26.3/92.7		30.8/91.9
Positive/negative LR	1.94/0.33	1.77/0.80	-		2.19/0.35	2.59/0.68	1.83/0.30	1.46/0.86	-	2.12/0.44		3.16/0.63
HR (95%CI)	2.61 (1.85-3.67)		1.85 (1.41-2.42)		2.09 (1.63-2.55)		1.59 (1.23-2.07)		2.64 (1.76-4.32)			2.13 (1.71-2.58)
FIB-4
AUROC (95%CI)	0.74 (0.69-0.79)		0.75 (0.69-0.80)		0.80 (0.75-0.84)		0.74 (0.67-0.80)		0.79 (0.73-0.84)			0.77 (0.71-0.83)
Cut-off values	-		1.45	3.25	-		-		1.45		3.25	-
Se/Sp (%)	-		87.9/47.3	42.6/87.2	-		-		77.5/58.1		37.5/93.1	-
PPV/NPV (%)	-		49.0/87.3	65.7/72.6	-		-		53.0/80.9		76.9/70.9	-
Positive/negative LR	-		1.67/0.25	3.34/0.66	-		-		1.85/0.39		5.46/0.67	-
HR (95%CI)	1.86 (1.52-2.53)		1.94 (1.55-2.42)		2.17 (1.77-2.56)		1.98 (1.50-2.62)		2.11 (1.63-2.74)			1.87 (1.68-2.36)
Comparison of AUROC
AGPR and GPR	P = 0.008		P < 0.0001		P = 0.0001		P = 0.028		P = 0.005			P = 0.0008
AGPR and APRI	P < 0.0001		P < 0.0001		P = 0.0002		P = 0.0001		P = 0.0001			P = 0.134
AGPR and FIB-4	P = 0.0004		P = 0.0005		P = 0.022		P = 0.007		P = 0.174			P = 0.100
GPR and APRI	P = 0.0007		P = 0.0028		P = 0.284		P = 0.003		P = 0.016			P = 0.831
GPR and FIB-4	P = 0.026		P = 0.331		P = 0.922		P = 0.093		P = 0.929			P = 0.591
APRI and FIB-4	P = 0.455		P = 0.028		P = 0.061		P = 0.248		P = 0.008			P = 0.795

AGPR: [Alkaline phosphatase (U/L) + gamma-glutamyl transpeptidase (U/L)]/platelet count (10⁹/L); AUROC: Area under the receiver operating characteristic curve; Se: Sensitivity; Sp: Specificity; PPV: Positive predictive value; NPV: Negative predictive value; LR: Likelihood ratio; HR: Hazard ratio; CI: Confidence interval; GPR: Gamma-glutamyl transpeptidase to platelet ratio; APRI: Aspartate aminotransferase-to-platelet ratio index; FIB-4: Age (years) × aspartate aminotransferase (U/L)/[platelet (10⁹/L) × alanine aminotransferase (U/L)^1/2].